Skip to main content
BLSM
NASDAQ Life Sciences

BlossomHill Aligns With FDA on Phase 2 Dose, Launches Pivotal SOLARA-2 Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$14.84
Mkt Cap
$471.688M
52W Low
$11.02
52W High
$27.99
52W Position info
35% above low
Off High info
47% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

BLSM sits 35% above its 52-week low of $11.02.

Summary

BlossomHill disclosed FDA alignment on 50 mg twice daily as the recommended Phase 2 dose for BH-30643 and announced SOLARA-2, a single-arm pivotal Phase 2 trial in EGFR C797S-positive NSCLC designed with registrational intent, with first patient dosing expected in Q1 2027. The company also struck a companion diagnostic collaboration with Foundation Medicine for the C797S resistance mutation. Q3 2026 net loss widened to $24.0 million, or $1.29 per share, from $16.0 million a year earlier, driven by R&D expenses of $21.9 million versus $14.7 million. Cash stood at $224.9 million as of September 30, 2026, which management says funds operations into Q2 2028. This follows the September SOLARA Phase 1/2 update showing a 45% objective response rate and the August Fast Track designation. Next catalysts: first patient dosed in SOLARA-2 in Q1 2027 and the BH-501284 IND filing the same quarter.

At the time of this announcement, BLSM was trading at $14.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.7M. The 52-week trading range was $11.02 to $27.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

BLSM - Latest Insights

BLSM
Nov 12, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.84
Real-time Price: $14.84 info
Change: $0 (0%) info
Market Cap: $471.688M info
BLSM
Sep 18, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.51
Real-time Price: $14.84 info
Change: -$11.67 (-44%) info
Market Cap: $471.688M info
BLSM
Sep 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $23.19
Real-time Price: $14.84 info
Change: -$8.35 (-36%) info
Market Cap: $471.688M info
BLSM
Aug 18, 2026, 4:53 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $16.10
Real-time Price: $14.84 info
Change: -$1.26 (-8%) info
Market Cap: $471.688M info
BLSM
Aug 18, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $17.14
Real-time Price: $14.84 info
Change: -$2.30 (-13%) info
Market Cap: $471.688M info